January 5, 2017 / 1:05 PM / 7 months ago

BRIEF-Avadel Pharmaceuticals provides 2017 guidance and business update

1 Min Read

Jan 5 (Reuters) - Avadel Pharmaceuticals Plc

* Avadel Pharmaceuticals provides 2017 guidance and business update

* Sees FY 2017 revenue $170 million to $200 million

* Avadel Pharmaceuticals Plc sees FY 2017 adjusted diluted EPS in range of $0.20 - $0.35

* Expects to finish 2016 near top end of revenue guidance of $133 to $143 million

* Avadel Pharmaceuticals Plc - plans to pursue approval from U.S. Food and Drug Administration for a sterile, injectable unapproved drug product Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below